@article{22947,
  author = {ANZICS Clinical Trials Group and Bellomo Rinaldo and Myburgh J and Webb Steven and Lipman Jeffrey and Paul Sanjoy and Udy Andrew and Dulhunty Joel and Roberts Jason and Davis Joshua and Gomersall Charles and Shirwadkar Charudatt and Eastwood Glenn and Paterson David and Starr Therese and BLING-II Investigators},
  title = {Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.},
  abstract = {<p>
Augmented renal clearance (ARC) is known to influence β-lactam antibiotic pharmacokinetics. This substudy of the BLING-II trial aimed to explore the association between ARC and patient outcomes in a large randomised clinical trial. BLING-II enrolled 432 participants with severe sepsis randomised to receive β-lactam therapy by continuous or intermittent infusion. An 8-h creatinine clearance (CLCr) measured on Day 1 was used to identify ARC, defined as CLCr ≥ 130 mL/min. Patients receiving any form of renal replacement therapy were excluded. Primary outcome was alive ICU-free days at Day 28. Secondary outcomes included 90-day mortality and clinical cure at 14 days following antibiotic cessation. A total of 254 patients were included, among which 45 (17.7%) manifested ARC [median (IQR) CLCr 165 (144-198) mL/min]. ARC patients were younger (P &lt;0.001), more commonly male (P = 0.04) and had less organ dysfunction (P &lt;0.001). There was no difference in ICU-free days at Day 28 [ARC, 21 (12-24) days; no ARC, 21 (11-25) days; P = 0.89], although clinical cure was significantly greater in the unadjusted analysis in those manifesting ARC [33/45 (73.3%) vs. 115/209 (55.0%) P = 0.02]. This was attenuated in the multivariable analysis. No difference was noted in 90-day mortality. There were no statistically significant differences in clinical outcomes in ARC patients according to the dosing strategy employed. In this substudy of a large clinical trial of β-lactam antibiotics in severe sepsis, ARC was not associated with any differences in outcomes, regardless of dosing strategy.
</p>
},
  year = {2017},
  journal = {Int J Antimicrob Agents},
  volume = {49},
  pages = {624-630},
  issn = {1872-7913},
  doi = {10.1016/j.ijantimicag.2016.12.022},
  language = {eng},
}